HeartSciences reports Q2 FY2025 zero revenue; cash $4.1M; MyoVista device on track for FDA submission Q1 2025

HeartSciences Inc.

2025-Q2 EPS reported -$4.88 vs consensus -$2.29 ▼ miss (-112.6%)

No revenue in Q2 FY2025; cash and equivalents $4.1M, shareholders' equity ~$4.0M at Oct 31, 2024.
MyoVista wav ECG device on track for FDA submission around Q1 2025; final pre-submission meeting with FDA requested.
MyoVista Insights Phase 1 (no regulatory clearance) completion by end of 2024; test sites targeted H1 2025. Phase 2 AI-ECG clearance target H2 2025.
Pre-validation of Mount Sinai-licensed low ejection fraction AI-ECG algorithm progressing; CMS 2025 OPPS final rule includes reimbursement path.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.